versión On-line ISSN 0717-9707
J. Chil. Chem. Soc. vol.56 no.2 Concepción 2011
J. Chil. Chem. Soc., 56, N° 2 (2011), págs.: 715-720
SENSITIVE AND SELECTIVE EXTRACTION FREE ION-PAIR COMPLEXOMETRIC DETERMINATION OF DOMPERIDONE IN PHARMACEUTICALS AND IN SPIKED HUMAN URINE
O ZENITA, K BASAVAIAH AND K B VINAY
Department of Chemistry. University of Mysore, Manasagangotri, Mysore-570006, India.
Domperidone (DOM) is a drug used as an antiemetic and to control gastrointestinal effects of dopaminergic drugs in the management of perkinsonism. Two simple, rapid, sensitive and selective extraction free spectrophotometric methods have been developed for the assay of DOM in pure drug, in pharmaceuticals and in spiked human urine sample. The methods are based on the formation of yellow ion-pair complexes between DOM and two sulphonphthalein dyes viz., thymol blue (method A) and bromothymol blue (method B) in acetone and dichloromethane medium. The complexes showed absorption maxima at 390 nm and 410 nm in method A and method B, respectively. Reaction conditions were optimized to obtain the maximum color intensity. The absorbance was found to increase linearly with increase in concentration of DOM, which was corroborated by the calculated correlation values of 0.9991 in method A and 0.9986 in method B. The systems obeyed Beer's law over the concentration range of 1.25 - 20 µg mL-1 in both the methods. The molar absorptivity values are calculated to be 1.53 x 104 and 2.06 X 104 L mol1 cm1 for method A and method B, respectively and the corresponding Sandell sensitivity values are 0.028 and 0.021 µg cm2. The composition of the ion-pairs was found to be 1 : 1 by Job's method and the conditional stability constant (Kf) of the complexes have been calculated. The proposed methods were applied successfully to the determination of DOM in tablets as well as in spiked urine sample with good accuracy and precision.
Keywords: Domperidone, Assay, Spectrophotometry, Sulphonphthalein dyes, Pharmaceuticals, Spiked urine.
Domperidone (DOM) is a D2-receptor antagonist used as an antiemetic. It is chemically known as 5-chloro-1-[1-3-(2-oxo-2, 3-dihydro-1H-benzimidazole-1-yl)propyl piperidin-4-yl]-1, 3-dihydro-2H-benzimidazol-2-one (Figure 1). It can be used in patients with Parkinson's disease1 and is also found to be effective in the treatment of gastroparesis.2 It is official in BP3 which recommends non-aqueous titration with perchloric acid as titrant and naphtholbenzein as indicator.
Literature survey revealed the availability of several methods for determination of domperidone in pharmaceutical formulations. Planar chromatography,4 high-performance liquid chromatography5-15 and high-performance thin-layer chromatography16-20 have been used to assay DOM. The drug has also been assayed by differential pulse voltammetry21 and anodic difference pulse voltammetry22 at a glassy carbon electrode in Britton-Robinson buffer. Application of potentiometric sensors23 for the analysis of DOM-containing tablets using PVC membrane and carbon paste sensors has also been reported. The most widely used technique for the assay of DOM has been UV spectrophotometry. Several UV-spectrophotometric24-36 procedures employing different media have been reported for assay in single as well as in combined dosage forms. There is only one report on the visible spectrophotometric assay of DOM in pharmaceuticals37 in which four procedures are described. The first two methods are based on redox-complexation reactions involving Fe3+, o-phenanthroline and bipyridyl37 and the other two methods utilize cerium (IV) as the oxidimetric reagent, which subsequently is determined by decrease of red color of chromotrope 2R or orange pink color of Rhodamine 6G.37 The reported four visible spectrophotometric methods37 involve a heating step and the procedures based on redox-complexation reactions require strict pH control. The reported chromatographic techniques although sensitive, require expensive instrumental-set up. A large volume of solvents is required for these techniques, which are expensive, hazardous to health, and harmful to the environment. HPLC requires precolumn derivatization without preliminary separation. Voltammetric and potentiometric sensor methods currently available involve rigid pH control.
Several chromatographic techniques such as liquid chromatography-mass spectrometry,38-40 ultra performance liquid chromatography41 and high-performance liquid chromatography42,43 have been reported for the determination of DOM in biological samples like human, dog and rat plasma. Many of these techniques are deficient in simplicity, cost-effectiveness and easy accessibility. No spectrophotometric method has ever been reported for assay of DOM in biological fluids. This prompted us to develop simple, sensitive and cost effective spectrophotometric methods for the assay of DOM in both pharmaceuticals and biological fluids.
In the present communication, the well-known ion-pair complex formation reaction has been employed for the determination of DOM in both pharmaceuticals and spiked human urine. The proposed methods have the advantages over the published methods in terms of simplicity, cost-effectiveness and freedom from cumbersome instrumentations.
All absorbance measurements were made on a Systronics model 106 digital spectrophotometer (Ahmedabad, India) equipped with 1-cm matched quartz cells.
Materials and Reagents
All chemicals and reagents used were of analytical-reagent grade. The solvents used were of HPLC-grade.
Standard DOM Solution
Pharmaceutical grade DOM certified to be 99.85% was kindly provided by Cipla India Ltd., Mumbai, India and was used as received. A stock standard solution of 200 µg mL-1 DOM was prepared by dissolving 20 mg of pure drug in 2.5 mL methanol and diluting to 100 mL in a calibrated flask with acetone in method A or with dichloromethane in method B. The 200 µg mL-1 DOM solution was diluted to get 25 µg mL-1 DOM with the respective solvents to use in method A and method B.
Two brands of tablets containing DOM, Domstal-10 (Torrent Pharmaceuticals Ltd., M. P, India) and Vemistop-10 (Cipla Ltd., H. P., India) used in the investigation were purchased from local commercial sources.
0.05 % Thymol Blue (TB) and 0.1 % Bromothymol Blue (BTB) The solutions were prepared by dissolving 0.050 g of thymol blue (Loba Chemie, Mumbai, India) in 100 mL of acetone (Merck, Mumbai, India) and 0.100 g of bromothymol blue (Loba Chemie, Mumbai, India) in 100 mL dichloromethane (Merck, Mumbai, India).
Construction of Calibration Curves
Aliquots of 0.25, 0.5, 1.0, 2.0, 3.0 and 4.0 mL DOM standard solution in acetone (25 µg mL-1) were measured accurately and transferred into a series of 5 mL calibrated flask. To each flask, 1 mL of 0.05 % TB solution was added, diluted to the mark with acetone and mixed well. The absorbance of the resulting yellow color chromogen was measured at 390 nm against reagent blank.
Varying aliquots, 0.25, 0.5, 1.0, 2.0, 3.0 and 4.0 mL of 25 µg mL-1 standard DOM solution in dichloromethane were measured accurately and transferred into a series of 5 mL calibrated flasks. To each flask was added 1 mL of 0.1% BTB. The content was mixed well and diluted to the mark with dichloromethane. The absorbance of each solution was measured at 410 nm against reagent blank.
In both methods, a calibration graph was prepared by plotting the increasing absorbance values versus concentration of DOM. The concentration of DOM was read from the calibration graph or computed from the respective regression equation derived using the Beer's law data.
Procedure for Tablets
Ten tablets were accurately weighed and powdered. A portion equivalent to 10 mg DOM was accurately weighed and transferred into two 50 mL calibrated flasks, 2.5 mL of methanol and 30 mL of acetone or dichloromethane were added to the flasks and the content was shaken thoroughly for 15 - 20 min to extract the drug into the liquid phase; the volume was finally diluted to the mark with either acetone or dichloromethane (50 mL flask), mixed well and filtered using a Whatman No. 42 filter paper. An aliquot of the filtrate (200 µg mL-1 in DOM) was further diluted to get 25 µg mL-1 DOM with respective solvents and analyzed by following the procedures described for the calibration curve.
Analysis of Urine Samples
A 5 mL volume of DOM - free human urine taken into a 125 mL separating funnel was spiked with 5 mg DOM. One mL of 3 M NaOH was added, mixed and kept aside for 3 min. Then 30 mL of ethyl acetate was added, shaken well for about 15 min and collected the upper organic layer in a beaker containing anhydrous sodium sulphate. The water-free organic layer was transferred into a dry beaker and evaporated on a hot water bath. The dry residue was dissolved in 2.5 mL methanol and transferred into a 50 mL calibrated flask, and diluted to the mark with acetone or dichloromethane. The resulting solution equivalent to 100 µg mL-1 DOM was further diluted to get 25 µg mL-1 DOM with respective solvents and analyzed by following the procedures described for the calibration curve.
Analysis of Placebo Blank
A placebo blank of the composition: talc (43 mg), starch (35 mg), acacia (25 mg), methyl cellulose (40 mg), sodium citrate (25 mg), magnesium stearate (35 mg) and sodium alginate (30 mg) was made and its solution was prepared in 25 mL calibration flask as described under "Procedure of Tablets", and then subjected to analysis using the procedures described above.
Analysis of Synthetic Mixture
To the placebo blank of the composition described above, 10 mg of DOM was added and homogenized, transferred to a 50 mL calibrated flask and the solution was prepared as described under "Procedure of Tablets", and then subjected to analysis by the procedures described above. The analysis was used to study the interferences of excipients such as talc, starch, acacia, methyl cellulose, sodium citrate, magnesium stearate and sodium alginate.
Procedure for Stoichiometric Relationship
Job's method of continuous variations of equimolar solutions was employed: 5.8698 x 10-5 M each of DOM and TB in acetone (method A) solutions; and 5.8698 x 10-5 M each of the DOM and BTB in dichloromethane (method B) solutions were prepared separately. A series of solutions was prepared in which the total volume of DOM and reagent was kept at 5 mL. The drug and reagent were mixed in various complementary proportions (0:5, 1:4, 2:3, 3:2. 4:1 and 5:0) and completed as directed under the recommended procedures. The absorbance of the resultant ion-pair complex was measured at 390 nm and 410 nm in method A and method B, respectively.
RESULTS AND DISCUSSION
Spectrophotometric technique based on extraction-free ion-pair complex formation reaction has received considerable attention in the recent years for the quantitative determination of many pharmaceuticals.44-47 Since, DOM is an amino compound; attempts were made to determine it by applying ion-pair complex formation reaction. In the preliminary experiments, anionic dyes like TB and BTB were found to give yellow colored ion-pair complexes with positively charged drug; based on this observation two spectrophotometric methods have been developed using TB and BTB as chromogenic agents.
Absorption spectra of the yellow colored ion-pair complexes DOM-TB and DOM-BTB are shown in Fig. 2 with absorption maxima at 390 and 410 nm, respectively. The developed yellow color is due to the conversion of the dye into an open quinoidal anionic derivative,48,49 which subsequently forms an ion pair with DOM as shown in Scheme 1.
Optimization of Reaction Conditions
Optimum reaction conditions for quantitative determination of ion-pair complexes were established via various preliminary experiments such as choice of organic solvent, concentration of the dye and reaction time.
Choice of Organic Solvent
DOM is practically insoluble in most of the organic solvents except methanol. However in methanolic medium, even the reagent blank gave an intense yellow color. Hence, DOM was dissolved in minimum quantity of methanol and a number of organic solvents such as dichloromethane, acetone, dioxane and carbon tetrachloride were examined to carry out the experiments. In the case of method A, acetone was found as the ideal solvent, since high sensitivity with minimum blank absorbance was achieved in acetone medium whereas in method B, dichloromethane was selected as the suitable solvent, yielding maximum absorbance. The blanks yielded least absorption in these solvents.
Effect of Dye Concentration
The influence of the concentration of TB and BTB on the intensity of the color developed at the selected wavelength was studied. In method A, the blank absorbance was found to increase with increasing concentration of TB as shown in Fig. 3. One mL of 0.05% TB gave maximum absorbance with minimum blank reading (Fig. 3). Hence, based on the sensitivity with minimum blank absorbance, 1 mL of 0.05% TB was used. In method B, constant absorbance readings were obtained when (0.5 - 2.0) mL of 0.1% BTB was used (Fig. 3) and the respective blanks gave negligible absorbance values. Hence, 1 mL of 0.1% BTB was fixed in method B.
Effect of Reaction Time
The optimum reaction time for the development of color at ambient temperature (30 ± 2oC) was studied and it was found that the addition of the dye solutions resulted in an immediate full color development. The formed ion pairs were stable for at least 40 min in method A and 30 min in method B.
Composition of Ion-Pair Complexes
The composition of ion-pair complexes was established by Job's method of continuous variations using variable dye and DOM concentrations. In both methods, the results indicated that 1: 1 (DOM:Dye) ion-pair complex is formed through the electrostatic attraction between the positively protonated drug and the anion of dye (Fig. 4). Based on these findings, we propose a probable reaction mechanism for the formation of the complex as shown in Scheme 1.
Conditional Stability Constants (Kf) of the Ion-Pair Complexes The conditional stability constants (Kf) of the ion-pair complexes for DOM were calculated from the continuous variation data using the following equation:50
where A and Am are the observed maximum absorbance and the absorbance value when all the drug present is associated, respectively. CM is the mole concentration of drug at the maximum absorbance and n is the stoichiometry with which dye ion associates with drug. The log Kf ± CL (Confidence limit at 95 %, n = 3) values for DOM - TB and DOM - BTB ion-pair associates were 6.457 ± 0.672 and 6.724 ± 0.561, respectively.
The proposed methods have been validated for linearity, sensitivity, precision, accuracy, robustness, ruggedness, selectivity and recovery according to the International Conference on Harmonization (ICH)51 guidelines.
Linearity and Sensitivity
Under optimum conditions, linear relations were obtained between absorbance and concentration of DOM in the range of 1.25 - 20 µg mL-1 in both methods (Fig. 5).
The calibration graph in each instance is described by the equation:
Y = a + b X
(Where Y = absorbance, a = intercept, b = slope and X = concentration in µg mL-1) obtained by the method of least squares. Correlation coefficient, intercept and slope for the calibration data are summarized in Table 1. Sensitivity parameters such as apparent molar absorptivity and Sandell sensitivity values, the limit of detection (LOD) and the limit of quantification (LOQ) are calculated as per the current ICH guidelines51 are compiled in Table 1 speak of the excellent sensitivity of the proposed methods. LOD and LOQ were calculated according to the same guidelines using the formulae: LOD = 3.3o/s and LOQ = 10o/s where o is the standard deviation of five reagent blank determinations and s is the slope of the calibration curve.
Precision and Accuracy
Intra-day precision and accuracy of the proposed methods were evaluated by replicate analysis (n = 7) of calibration standards at three different concentration levels in the same day. Inter-day precision and accuracy were determined by assaying the calibration standards at the same concentration levels on five consecutive days. Precision and accuracy were based on the calculated relative standard deviation (RSD, %) and relative error (RE, %) of the found concentration compared to the theoretical one, respectively (Table 2).
Robustness and Ruggedness
Method robustness was tested by making small incremental change in concentration of TB in method A and BTB in method B. To check the ruggedness, analysis was performed by four different analysts; and on three different spectrophotometers by the same analyst. The robustness and the ruggedness were checked at three different drug levels. The intermediate precision, expressed as percent RSD, which is a measure of robustness and ruggedness was within the acceptable limits as shown in Table 3.
The proposed methods were tested for selectivity by placebo blank and synthetic mixture analyses. A convenient aliquot of the placebo blank solution was subjected to analysis according to the recommended procedures. In both methods, there was no interference by the inactive ingredients as indicated by the near blank absorbance.
A separate experiment was performed with the synthetic mixture. The analysis of synthetic mixture solution yielded percent recoveries which ranged of 103.5 - 105.7 with standard deviation of 1.37 - 1.97 in both methods. The results of this study are presented in Table 4 indicating that the inactive ingredients did not interfere in the assay. These results further demonstrate the accuracy as well as the precision of the proposed methods.
Application to Analysis of Spiked Urine Sample and Tablets
The proposed methods were successfully applied to the determination of DOM in spiked urine sample with mean percent recovery ± S. D. in the range of 106.5 - 109.2 (n = 5) ± 1.68 - 2.09 in both methods (Table 5). In order to evaluate the analytical applicability of the proposed methods to the quantification of DOM in commercial tablets, the results obtained by the proposed methods were compared to those of the reference method3 by applying Student's t-test for accuracy and F-test for precision. The reference method describes non-aqueous titration with perchloric acid as titrant and naphtholbenzein as indicator. The results (Table 6) show that the Student's t- and F-values at 95 % confidence level are less than the theoretical values, which confirmed that there is a good agreement between the results obtained by the proposed methods and the reference method with respect to accuracy and precision.
The accuracy and validity of the proposed methods were further ascertained by performing recovery studies. Pre-analyzed tablet powder was spiked with pure DOM at three concentration levels (50, 100 and 150 % of that in tablet powder) and the total was found by the proposed methods. In both methods, the added DOM recovery percentage values ranged of 99.6 - 108.8 % with standard deviation of 1.41 - 1.98 (Table 7) indicating that the recovery was good, and that the co-formulated substance did not interfere in the determination.
The present communication reports the first spectrophotometric assay of DOM in biological fluid. The proposed methods are simple, rapid and selective compared to the published visible spectrophotometric methods of DOM in pharmaceuticals. The reported four visible spectrophotometric methods37 of DOM require boiling for 5 - 10 min and in addition to this, the procedures based on redox-complexation reaction also require strict pH control. In contrast to these methods,37 the present methods can be applied at ambient temperature, color development is instantaneous and neither involves complicated extraction procedure nor requires strict pH control. Besides the simplicity and sensitivity of the procedures, the relative cheapness of apparatus and reagents demonstrate their advantageous characteristics. The methods are also useful due to high tolerance limit for common excipients found in drug formulations. These merits coupled with the use of simple and inexpensive instrument and high selectivity of the methods recommend the use of the methods in routine quality control Laboratories.
The authors wish to acknowledge, Cipla India Ltd, Mumbai, India, for providing the gift sample of domperidone. OZD and KBV thank the authorities of the University of Mysore, Mysore, for permission and facilities. One of the authors (OZD) also wishes to thank University Grant Commission (UGC), New Delhi, India, for the award of UGC Meritorious Research Fellowship.
1.J. S. Shindler, G. T. Finnerty, K. Towlson, A. L. Dolan, C. L. Davies, J. D. Parkes, Br. J. Clin. Pharmacol. 18, 959, (1984). [ Links ]
2.D. Silvers, M. Kipnes, V. Broadstone, Clin. Ther. 20, 438, (1998). [ Links ]
3.British Pharmacopoeia, London: H. M. Stationary Office, 572 (2009). [ Links ]
4.A. G. Seema, A. S. Atul, S. J. Yogini, J. S. Sanjay, J. Planar Chromatogr.Mod. TLC. 19, 302, (2006). [ Links ]
5.T. Sivakumar, R. Manavalan, K. Valliappan, Acta Chromatogr. 18, 131, (2007). [ Links ]
6.M. Veronique, S. Chantal, T. Jacques, J. Chromatogr. B. 852, 611, (2007). [ Links ]
7.R. Kalirajan, K. Anandarajagopal, S. Mary Mathew, B. Gowramma, S. Jubie, B. Suresh, Rasayan J. Chem. 1, 232, (2008). [ Links ]
8.B. H. Patel, B. N. Suhagia, M. M. Patel, J. R. Patel, Chromatographia. 65, 743, (2007). [ Links ]
9.B. Patel, Z. Dedania, R. Dedania, C. Ramolia, G. Vidya Sagar, R. S. Mehta, Asian J. Research Chem. 2, 210, (2009). [ Links ]
10.L. Sivasubramanian, V. Anilkumar, Indian J. Pharm. Sci. 69, 674, (2007). [ Links ]
11.B. H. Patel, M. M. Patel, J. R. Patel, B. N. Suhagia, J. Liq. Chromatogr. Rel. Technol. 30, 439, (2007). [ Links ]
12.A. Karthik, G. Subramanian, A. Ranjith Kumar, N. Udupa, Indian J. Pharm. Sci. 9, 142, (2007). [ Links ]
13.A. P. Argekar, S. J. Shah, J. Pharm. Biomed. Anal. 19, 813, (1999). [ Links ]
14.S. S. Sabnis, N. D. Dhavale, V. J. Jadhav, S. V. Gandhi, J. AOAC Int. 91, 344, (2008). [ Links ]
15.S. Thanikachalam, M. Rajappan, V. Kannappan, Chromatographia, 67, 41, (2008). [ Links ]
16.B. H. Patel, B. N. Suhagia, M. M. Patel, J. R. Patel, J. AOAC Int. 90, 142, (2007). [ Links ]
17.B. H. Patel, B. N. Suhagia, M. M. Patel, J. R. Patel, J. Chromatogr. Sci. 46, 304, (2008). [ Links ]
18.B. H. Patel, M. M. Patel, J. R. Patel, B. N. Suhagia, J. Liq. Chromatogr. Rel. Technol. 30, 1749, (2007). [ Links ]
19.A. Yadav, M. Raman Singh, C. Satish Mathur, K. Pawan Saini, N. Gyanendra Singh, J. Planar Chromatogr-Mod TLC. 22, 421, (2009). [ Links ]
20.J. V. Susheel, M. Lekha, T. K. Ravi. Indian J. Pharm. Sci. 69, 684, (2007). [ Links ]
21.M. S. El-Shahawi, S. O. Bahaffi, T. El-Mogy, Anal. Bioanal. Chem. 387, 719, (2007). [ Links ]
22.T. Wahdan, N. Abd El-Ghany, IL Farmaco. 60, 830, (2005). [ Links ]
23.K. Girish Kumar, P. Augustine, S. John, J. Appl. Electrochem. 40, 65, (2010). [ Links ]
24.K. I. Al-khamis, M. E. M. Hagga, H. A. Al-khamees, M. Al-awadi, Anal. Lett. 23, 451, (1990). [ Links ]
25.A. P. Sherje, A. V. Kasture, K. N. Gujar, P. G. Yeole, Indian J. Pharm. Sci. 70, 102, (2008). [ Links ]
26.S. Shweta Sabnis, D. Nilesh Dhavale, Y. Vijay Jadhav, R. Santosh Tambe, V. Santosh Gandhi, Eurasian J. Anal. Chem. 3, 236, (2008). [ Links ]
27.M. E. Mohamed, H. A. Al-Khamees, M. Al-Awadi, K. I. Al-Khamis, IL Farmaco, 44, 1045, (1989). [ Links ]
28.K. Kapil, S. Naik, J. Garima, N. Mishra, Asian J. Research Chem. 2, 112, (2009). [ Links ]
29.Y. Rajendraprasad, K. K. Rajasekhar, V. Shankarananth, H. V. Yaminikrishna, S. Saikumar, P. Venkata raghav reddy, J. Pharm. Res. 2, 1593, (2009). [ Links ]
30.Y. Maissa Salem, G. Mohamed El-Bardicy, F. Mohamed El-Tarras, S. Eman El-Zanfally, J. Pharm. Biomed. Anal. 30, 21, (2002). [ Links ]
31.S. P. Lakshmana, A. Shirwaikar, A. Shirwaikar, C. Dinesh Kumar, A. Joseph, R. Kumar, Indian J. Pharm. Sci. 70, 128, (2008). [ Links ]
32.R. Sahu, N. Preeti, S. Bhattacharya, J. Deepti, Indian J. Pharm. Sci. 68, 503, (2006). [ Links ]
33.M. Y. Salem, E. S. El-Zanfaly, M. F. El-Tarras, M. G. El-Bardicy, Anal. Bioanal. Chem. 375, 211, (2003). [ Links ]
34.P. Ravi Kumar, P. Bhanu Prakash, M, Murali Krishna, M. Santha Yadav, C. Asha Deepthi, E-J. Chem. 3, 142, (2006). [ Links ]
35.M. Charde, S. Walode, M. Tajne, A. Kasture, Indian J. Pharm. Sci. 68, 660, (2006). [ Links ]
36.M. Charde, S. Walode, M. Tajne, A. Kasture, Indian J. Pharm. Sci. 68, 658, (2006). [ Links ]
37.S. Alaa Amin, H. Gamal Ragab, Anal. Sci. 19, 747, (2003). [ Links ]
38.M. S. Wu, L. Gao, X. H. Cai, G. J. Wang, Acta Pharmacol. Sin. 23, 285, (2002). [ Links ]
39.L. Zhan, Y. Jing, Z. Ziqiang, Z. Luyong, J. Chromatogr. Sci. 47, 881, (2009). [ Links ]
40.A. Bose, U. Bhaumik, A. Ghosh, B. Chatterjee, U. S. Chakrabarty, A. K. Sarkar, T. K. Pal, Chromatographia. 69, 1233, (2009). [ Links ]
41.X. Dong-Hang, L. Hong-Gang, Y. Hong, J. Bo, Z. Quan, Z. Zhong-Miao, R. Zou-Rong, Biomed. Chromatogr. 22, 433, (2008). [ Links ]
42.Y. Koujirou, H. Mami, K. Hajime, I. Tatsuji, J. Chromatogr. B. 720, 251, (1998). [ Links ]
43.T. Sivakumar, R. Manavalan, K. Valliappan, Acta Chromatogr. 20, 549, (2008). [ Links ]
44.H. Abdine, F. Belal, N. Zoman, IL Farmaco. 57, 267, (2002). [ Links ]
45.S. M. Al-Ghannam, J. Pharm. Biomed. Anal. 40, 151, (2006). [ Links ]
46.P. Shahdousti, M. Aghamohammadi, N. Alizadeh, Spectrochim. Acta A. 69, 1195, (2008). [ Links ]
47.D. H. Manjunatha, S. M. T. Shaikh, K. Harikrishna, R. Sudhirkumar, P. B. Kandagal, J. Seetharamappa, Eclet. Quim. 33, 37, (2008). [ Links ]
48.S. Ashour, M. F. Chehna, R. Bayram, Int. J. Biomed. Sci. 2, 273, (2006). [ Links ]
49.T. Higuchi, E. Brochmann-Hanssen, Pharmaceutical Analysis. Interscience Publication, New York, 1961; pp. 413-418. [ Links ]
50.A. S. Amin, A. A. El-Fetouh Gouda, R. El-Sheikh, F. Zahran, Spectrochim. Acta A. 67, 1306, (2007). [ Links ]
51.International Conference On Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonized Tripartite Guideline, Validation of Analytical Procedures: Text and Methodology Q2(R 1), Complementary Guideline on Methodology dated 06 November 1996, incorporated in November 2005, London. [ Links ]
(Received: February 27, 2011 - Accepted: April 26, 2011).
*Corresponding author: Kanakapura Basavaiah, Department of Chemistry, University of Mysore Manasagangotri, Mysore-570006, India. e-mail: firstname.lastname@example.org